In this episode of the Oncology Brothers podcast, we dived deep into the complexities of multiple myeloma treatment, focusing on the groundbreaking MajesTEC-3 trial. We had the pleasure of welcoming Dr. Luciano Costa from the University of Alabama, who shared insights on the combination of teclistamab and daratumumab for relapsed refractory multiple myeloma.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Key topics discussed included:

The impressive progression-free survival (PFS) rates observed in the MajesTEC-3 trial, with a PFS of 83.4% at three years.
The mechanism of action of teclistamab as a bispecific antibody targeting BCMA and its synergy with daratumumab.
Safety profiles, including the management of cytokine release syndrome (CRS) and infection risks, along with the use of IVIG for prophylaxis.
The evolving landscape of multiple myeloma therapies, including the role of CAR T-cell therapy versus bispecific antibodies.

Join us for this informative discussion that aims to keep healthcare professionals updated on the latest advancements in multiple myeloma treatment. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!

#MultipleMyeloma, #MajesTEC3, #Teclistamab, #Daratumumab, #BispecificAntibody, #OncBrothers

Teclistamab-Daratumumab FDA Approval of MajesTEC-3 for R/R Multiple Myeloma (MM): Dr. Luciano Costa

Oncology Brothers: Practice-Changing Cancer Discussions

Teclistamab-Daratumumab FDA Approval of MajesTEC-3 for R/R Multiple Myeloma (MM): Dr. Luciano Costa